TOPLINE:

Among patients with a first episode or first recurrence of Clostridioides difficile infection (CDI), a 4-week vancomycin pulse and taper regimen had about 74% probability of reducing risk for recurrence by day 56 and a 99% probability by day 38 compared with a standard 2-week pulse regimen; this apparent benefit may reflect delayed rather than prevented recurrences. 

METHODOLOGY:

• This randomized clinical trial at 12 hospitals evaluated whether a 4-week vancomycin pulse and taper regimen was superior to standard 2-week pulse regimen in reducing the risk for recurrent CDI among patients with a first episode or first recurrence.
• A total of 265 patients (median age, 63 years; 52.1% women) received a standard 14-day course of vancomycin (125 mg orally four times daily). On day 15, they were assigned to a vancomycin taper (n = 135; 125 mg orally twice daily for 7 days, then 125 mg once daily for 7 days) or a matching placebo following the same taper schedule (n = 130).
• CDI was defined as having three or more episodes of diarrhea within 24 hours, accompanied by laboratory confirmation; for patients with fewer stools, a positive finding of ileus, toxic megacolon, or pseudomembranous colitis on colonoscopy was required.
• The primary outcome was recurrent CDI requiring treatment between days 15 and 56; secondary outcomes included recurrence on day 38 and adverse effects.
• Follow-up assessments were conducted on days 28 and 56, with periodic check-ins through day 90.

TAKEAWAY:

• At day 56, recurrence occurred in 14.8% of the vancomycin pulse and taper group and 17.7% of the placebo group (adjusted relative risk [aRR], 0.84; 95% credible interval [CrI], 0.48-1.45; posterior probability of superiority, 73.8%).
• At day 38, recurrence occurred in 6.7% of the vancomycin pulse and taper group vs 15.4% of the placebo group (aRR, 0.43; 95% CrI, 0.19-0.89; posterior probability of superiority, 99.0%).
• Adverse effects were generally mild, occurring in 11.4% of the vancomycin pulse and taper group compared with 10.1% of the placebo group; discontinuation due to adverse effects was 1.5% vs 2.3%, respectively.

IN PRACTICE:

“This approach may represent a safe and accessible treatment option to delay or prevent early CDI recurrence,” the authors wrote.

SOURCE:

The study was led by Emily G. McDonald, MD, MSc, McGill University, Montreal, Quebec, Canada. It was published online on February 27, 2026, in JAMA Network Open.

LIMITATIONS:

The trial ended early, reducing the statistical power to detect a benefit on day 56. Both the initial diagnosis and recurrence were assessed primarily with nucleic acid amplification testing in patients with clinical symptoms. The control group received a 14-day initial course of vancomycin, which may have biased the results toward no observable effect. 

DISCLOSURES:

The trial was funded by the Canadian Institutes of Health Research. Several authors disclosed receiving research salary support, personal fees, consulting fees, or grant support; serving on advisory boards; or having other ties with various pharmaceutical companies and institutions, including the Canadian Institutes of Health Research.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.